Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Research UK

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

- PMLiVE

FDA approves another home genetic testing service

23andMe’s kit will check for an increased risk of certain cancers developing

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

Eli Lilly HQ

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

Studies show the drug improves PFS when used with an aromatase inhibitor

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

- PMLiVE

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links